Collection of Blood Samples for New Diagnostic Devices 2

Launched by LUMIRADX UK LIMITED · Oct 3, 2022

Keywords

ClinConnect Summary

This clinical trial, titled "Collection of Blood Samples for New Diagnostic Devices 2," is focused on developing new tools to help doctors quickly and accurately diagnose various health conditions, such as blood clots, heart issues, infections, and kidney disorders. The goal is to create better tests that can give results right at the doctor's office, improving how patients are monitored and treated.

To participate in the trial, you need to be at least 18 years old and capable of giving your consent. You should also be visiting a healthcare team involved in this research. Participants are grouped based on their symptoms: for example, some may have signs of blood clots, while others might have infections or heart problems. If you decide to join, you'll provide blood samples, and your involvement will help advance medical testing. It's important to note that this study is currently recruiting participants, and it aims to enhance patient care by making diagnostic processes more efficient.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • Subject 18 years of age.
• • Willing and able to provide written informed consent and comply with study procedures.
• • Patients attending a definitive care team with research capabilities which has been enroled in this collection study.
• • Patients who can read and understand written English.
• * The subject must present as one of the following cohorts:
• • 1. Group A - Embolism Cohort - Patients presenting with symptoms indicative of thromboembolic events.
• • 2. Group B - Infection or Inflammation Cohort - Patients presenting with symptoms indicative of infection or inflammatory disorders.
• • 3. Group C - Cardiovascular Cohort - Patients presenting with symptoms indicative of heart failure or acute coronary syndrome.
• • 4. Group D - Renal Cohort - Patients presenting with symptoms indicative of renal disorders.
• • 5. Group E - Other Cohort. - Patients who are not eligible for any of the above groups.
• • Exclusion Criteria
• • Subject \<18 years of age.
• • Vulnerable populations deemed inappropriate for the study by the sites Principal Investigator.
• • Patients who have previously been enroled in any LumiraDx NOVEL study in the past 3 months and re-entry would breach the 24mL and or 6 fingersitck maximums.